Company Overview

Imunon, Inc. is a U.S.-based clinical-stage biotechnology company focused on developing nucleic acid-based immunotherapies and next-generation non-viral DNA delivery technologies. The company operates primarily in the oncology and infectious disease sectors, with research centered on DNA-mediated immunotherapy, cytokine-based cancer treatments, and vaccine delivery systems. Imunon’s core platform technologies include its proprietary TheraPlas and PlaCCine delivery systems, which are designed to enhance cellular uptake and expression of DNA-based therapeutics. The company’s primary revenue sources historically have included research collaborations, grants, and capital market financing, as it remains in the clinical development stage without approved commercial products.

The company was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in 2022 to reflect its strategic transition toward immunotherapy and DNA-based therapeutics. Its lead clinical candidate, IMNN-001, is being evaluated for the treatment of advanced ovarian cancer through localized IL-12 immunotherapy delivered via the company’s proprietary platform. Imunon positions itself within the biotechnology sector as a developer of non-viral gene-based therapies intended to improve immune activation while reducing systemic toxicity associated with conventional cancer therapies.

Business Operations

Imunon conducts operations primarily through its biotechnology research and clinical development activities in the United States. The company’s principal business units revolve around its TheraPlas DNA delivery platform for immunotherapy applications and the PlaCCine platform for nucleic acid vaccine development. Revenue generation remains limited because the company has not commercialized any approved therapies; operations are primarily financed through equity offerings, strategic collaborations, licensing arrangements, and government or institutional research support.

The company’s lead asset, IMNN-001, is undergoing clinical evaluation in ovarian cancer and represents the central focus of current operations. Imunon also continues preclinical and early-stage development efforts involving infectious disease vaccine applications using its PlaCCine technology. The company maintains relationships with clinical research organizations, academic institutions, and manufacturing partners to support trial execution and product development. Public filings identify collaborations and outsourced manufacturing arrangements as important operational components, though no large-scale commercial joint ventures have been publicly disclosed.

Strategic Position & Investments

Imunon’s strategic direction centers on advancing localized immunotherapy approaches using non-viral DNA delivery technologies. The company has prioritized development of IMNN-001 as its flagship oncology candidate, particularly targeting ovarian cancer indications where unmet medical need remains significant. Strategic efforts have focused on generating clinical efficacy data, expanding intellectual property protection, and demonstrating the broader applicability of the company’s delivery technologies across oncology and infectious disease settings.

The company has invested in expanding and validating its proprietary TheraPlas and PlaCCine platforms as differentiated alternatives to viral-vector delivery systems. Imunon’s research emphasis includes cytokine-based immunotherapies, DNA vaccines, and cell-mediated immune activation technologies. While the company has explored broader platform applications and potential partnership opportunities, publicly available information does not confirm major acquisitions or large subsidiary investment structures. Data inconclusive based on available public sources regarding material portfolio company holdings or significant international equity investments.

Geographic Footprint

Imunon is headquartered in Lawrenceville, New Jersey, and its operational footprint is concentrated primarily within the United States. Clinical development activities, regulatory operations, and executive management are U.S.-based, while clinical trial execution may involve research sites across multiple domestic regions. The company operates within the broader global biotechnology and pharmaceutical ecosystem through research collaborations, manufacturing relationships, and participation in international scientific and clinical networks.

Although Imunon does not maintain the extensive multinational commercial infrastructure typical of large pharmaceutical companies, its therapeutic development programs target global oncology and infectious disease markets. The company’s technologies are designed for potential international applicability, particularly in immunotherapy and vaccine development sectors. Public disclosures indicate limited direct international operating infrastructure at present, with global influence primarily occurring through clinical research engagement and intellectual property positioning.

Leadership & Governance

Imunon’s leadership team is composed of biotechnology, pharmaceutical, and clinical development executives with experience in oncology therapeutics, corporate strategy, and capital markets. The company’s governance approach emphasizes advancing clinical-stage assets through disciplined development milestones, regulatory engagement, and platform technology validation. Since transitioning from Celsion Corporation to Imunon, management has publicly emphasized a strategic focus on DNA-mediated immunotherapy and precision delivery technologies.

Key executives include:

• Stacy R. Lindborg, Ph.D. – President and Chief Executive Officer
• Jeffrey W. Church – Chief Financial Officer
• Michael H. Tardugno – Executive Chairman
• Corinne Le Goff, Pharm.D. – Director
• Karl G. Wittig, CPA – Director

The company’s leadership strategy has consistently focused on advancing clinical oncology programs while leveraging proprietary delivery platforms for broader therapeutic applications. Governance and operational disclosures are primarily provided through SEC filings, including annual reports and investor communications.